Upcoming FDA regulatory event · expected window, no date published

The FDA’s second peptide meeting

The FDA has signalled a further Pharmacy Compounding Advisory Committee (PCAC) meeting on five peptides - LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF - before the end of February 2027. No date has been published, and until the Federal Register notice appears, none exists. This page holds what is actually known, updates when anything official moves, and - unlike the coverage that will arrive with the headlines - explains now what a vote would and would not change.

The five substances

All five were moved out of the FDA’s Category 2 grouping in April 2026 with committee reviews signalled - a procedural step that authorized nothing by itself. Two are tracked as full atlas entries today:

  • LL-37A human-derived antimicrobial peptide, among the group the FDA moved out of Category 2 in April 2026 with a committee review signalled.
  • Dihexa acetateA synthetic peptide from the same April 2026 group; like the others, moving out of Category 2 did not authorize compounding.
  • PEG-MGFA pegylated growth-factor fragment from the same group, awaiting the same committee review.

The remaining three join the atlas as full entries when the FDA publishes meeting materials worth citing - briefing documents, vote questions, and a roster, as it did for the July 2026 meeting.

What a vote would change - and what it would not

The question before the committee, for each substance, is whether it should be added to the 503A Bulk Drug Substances List - the list that determines what a state-licensed pharmacy may compound against a prescription. A favorable vote is real forward motion and still changes nothing by itself: PCAC votes are advisory, and listing requires the FDA to accept a recommendation and complete rulemaking, generally estimated at 12 to 24 months.

The July 2026 meeting is the working precedent: the committee recommended six of seven peptides - overriding FDA review staff who proposed against all of them - and as of Aug 22, 2026 (ET), none of the six is legal to compound. Every vote and tally is here. Expect the same day-after pattern in 2027: headlines reading "FDA clears", and a legal reality that has not moved.

What to watch, in order

  1. The Federal Register meeting notice - dates, docket number, agenda. This is the moment "expected" becomes "scheduled". FDA documents in the Federal Register
  2. FDA briefing documents - the agency’s own scientific position on each substance, published shortly before the meeting. In July, FDA reviewers proposed against listing every peptide reviewed.
  3. The votes - advisory tallies, usually reported same-day by trade press before the FDA publishes minutes.
  4. Rulemaking, if any - the only step that changes a legal status, and it follows months to years later.

Asked and answered

When is the FDA’s second peptide compounding meeting?
No date has been published. The FDA has signalled a further Pharmacy Compounding Advisory Committee (PCAC) meeting before the end of February 2027. The real trigger to watch is the Federal Register meeting notice, which sets the dates, docket, and agenda - it can publish on any business day, typically several weeks before the meeting.
Which peptides is the meeting expected to cover?
Five substances: LL-37, GHK-Cu, Dihexa acetate, Melanotan II, PEG-MGF. All five were moved out of the FDA's Category 2 grouping in April 2026 with committee reviews signalled - a procedural shift that did not itself authorize compounding any of them.
If the committee votes in favor, do these peptides become legal to compound?
No. PCAC votes are advisory: they do not bind the FDA, and they change no legal status on the day of the vote. The July 2026 meeting is the proof - the committee recommended six of seven peptides, and none of them is legal to compound today. Listing requires the FDA to accept a recommendation and complete rulemaking, generally estimated at 12 to 24 months.
What happened at the first peptide meeting in July 2026?
On July 23-24, 2026 the committee reviewed seven peptides - including BPC-157, TB-500 and Semax - and recommended six, overriding FDA review staff who had proposed against listing all seven. Every vote, tally, and the legal reality is recorded on the July 2026 results page.

Sources